Cadila Healthcare is amongst the top three gainers on the BSE; it rose over 5% at Rs.486.05, with volumes up over one time. Its 52-week high stands at Rs.558.

The market is happy with the news that it has received final approval from the US health regulator to market anti-psychotic Ziprasidone Hydrochloride capsules in the American market. The company has received the final approval from the United States Food and Drug Administration (USFDA) to market Ziprasidone Hydrochloride capsules in strengths of 20 mg, 40 mg, 60 mg, and 80 mg.

The drug is used to treat schizophrenia and the manic symptoms of bipolar disorder. These capsules will be made at the group's formulations manufacturing facility at the Pharma SEZ, Ahmedabad.